Patent · US Active

Treatment of fragile X syndrome

US10864182B2 · kind B2 · utility

1Cited by
0References
17Claims
0Family size

Assignee

Inventor

Key dates

Filing dateApr 12, 2019
Grant dateDec 15, 2020
Priority date—
Expiry dateApr 12, 2039

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P25/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Described herein is the use of sulindac in the treatment of fragile X syndrome (FXS).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.